{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:46:46Z","timestamp":1762642006651,"version":"3.44.0"},"reference-count":44,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,9,13]]},"abstract":"<jats:p>Several hepatobiliary disorders have been reported in ulcerative colitis (UC) patients with primary sclerosing cholangitis (PSC) being the most specific. Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, rarely occurs in UC. We present two PBC cases of 67 and 71 years who suffered from long-standing UC. Both patients were asymptomatic but they had increased cholestatic enzymes and high titres of antimitochondrial antibodies (AMA)\u2014the laboratory hallmark of PBC. After careful exclusion of other causes of cholestasis by MRI\/magnetic resonance cholangiopancreatography (MRCP), virological and microbiological investigations, a diagnosis of PBC associated with UC was established. The patients started ursodeoxycholic acid (13\u2009mg\/kg\/day) with complete response. During follow-up, both patients remained asymptomatic with normal blood biochemistry. Although PSC is the most common hepatobiliary manifestation among patients with UC, physicians must keep also PBC in mind in those with unexplained cholestasis and repeatedly normal MRCP. In these cases, a reliable AMA testing can help for an accurate diagnosis.<\/jats:p>","DOI":"10.1136\/bcr-2017-220824","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T03:05:15Z","timestamp":1506395115000},"page":"bcr-2017-220824","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis"],"prefix":"10.1136","volume":"2017","author":[{"given":"Erietta","family":"Polychronopoulou","sequence":"first","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Lygoura","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos K","family":"Gatselis","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George N","family":"Dalekos","sequence":"additional","affiliation":[{"name":"Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12794"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/liv.13265","article-title":"Hepatic manifestations of inflammatory bowel diseases","volume":"37","author":"Restellini","year":"2017","journal-title":"Liver Int"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.3","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MPG.0000000000001492","article-title":"Hepatic issues and complications associated with inflammatory bowel disease: a clinical report from the NASPGHAN inflammatory bowel disease and hepatology committees","volume":"64","author":"Saubermann","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17530059.2.6.621","article-title":"Molecular diagnostics of primary biliary cirrhosis","volume":"2","author":"Rigopoulou","year":"2008","journal-title":"Expert Opin Med Diagn"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14737159.2016.1217159","article-title":"Molecular diagnostic testing for primary biliary cirrhosis","volume":"16","author":"Gatselis","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1478-3231.2010.02366.x","article-title":"A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre","volume":"31","author":"Floreani","year":"2011","journal-title":"Liver Int"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.10","first-page":"2012","article-title":"Prevalence and long term\u00a0course of primary biliary cirrhosis in primary Sj\u00f6gren\u2019s syndrome","volume":"35","author":"Hatzis","year":"2008","journal-title":"J Rheumatol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.11","first-page":"179","article-title":"Primary biliary cirrhosis associated with anticardiolipin syndrome","volume":"6","author":"Dalekos","year":"1995","journal-title":"Eur J Intern Med"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01402.x"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cca.2009.12.012","article-title":"Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis","volume":"411","author":"Liaskos","year":"2010","journal-title":"Clin Chim Acta"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.14","doi-asserted-by":"crossref","unstructured":"Gatselis NK , Zachou K , Dalekos GN . Early primary biliary cirrhosis: a new association with erythema nodosum of unknown origin. Gastroenterol Res Pract 2010;121620.","DOI":"10.1155\/2010\/121620"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.cca.2012.05.015","article-title":"IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases","volume":"413","author":"Gatselis","year":"2012","journal-title":"Clin Chim Acta"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2006.01.002"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.029"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.18","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejim.2017.05.006","article-title":"Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece","volume":"42","author":"Gatselis","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.21","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12470"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(02)00089-4"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.08.002"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/00365520310008746","article-title":"Anti-sp100 antibodies in primary biliary cirrhosis","volume":"39","author":"Rigopoulou","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9092-0"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.28","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2013.801461"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3748\/wjg.v21.i1.60","article-title":"Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics","volume":"21","author":"Gatselis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/liv.12658","article-title":"Anti-SLA\/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis","volume":"35","author":"Zachou","year":"2015","journal-title":"Liver Int"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.32","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3748\/wjg.v9.i4.878","article-title":"Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature","volume":"9","author":"Xiao","year":"2003","journal-title":"World J Gastroenterol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.33","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2169\/internalmedicine.50.5919","article-title":"Ulcerative colitis complicated with primary biliary cirrhosis","volume":"50","author":"Tada","year":"2011","journal-title":"Intern Med"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.34","first-page":"900","article-title":"Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis","volume":"107","author":"Arai","year":"2010","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.35","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-3057-z"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.36","first-page":"354","article-title":"Primary biliary cirrhosis associated with ulcerative colitis","volume":"92","author":"Nakayama","year":"2001","journal-title":"Fukuoka Igaku Zasshi"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.37","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1023\/A:1026697613173","article-title":"Ulcerative colitis associated with primary biliary cirrhosis","volume":"44","author":"Koulentaki","year":"1999","journal-title":"Dig Dis Sci"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.38","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/0016-5085(87)90636-6","article-title":"Primary biliary cirrhosis and ulcerative colitis","volume":"92","author":"Bush","year":"1987","journal-title":"Gastroenterology"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.03.003"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.40","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.41","first-page":"101","article-title":"Crohn\u2019s disease of the small bowel, complicated by primary biliary cirrhosis, Hashimoto thyroiditis, and Raynaud\u2019s phenomenon: favorable response of all disorders to adalimumab treatment","volume":"6","author":"Triantafillidis","year":"2013","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.02.029","article-title":"Use of TNF\u03b1 antagonists in refractory AIH: revealing the unforeseen","volume":"59","author":"Saitis","year":"2013","journal-title":"J Hepatol"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"2025082701381025000_2017.sep25_1.bcr-2017-220824.44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00042737-200404000-00011","article-title":"Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase","volume":"16","author":"Zachou","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-220824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:38:25Z","timestamp":1756283905000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-220824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":44,"alternative-id":["10.1136\/bcr-2017-220824"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-220824","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,9,25]]}}}